{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:38:48Z","timestamp":1785523128241,"version":"3.56.0"},"reference-count":140,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>High grade serous carcinoma (HGSC) is one of the most lethal ovarian cancers that is characterised by asymptomatic tumour growth, insufficient knowledge of malignant cell origin and sub-optimal detection. HGSC has been recently shown to originate in the fallopian tube and not in the ovaries. Conventional treatments such as chemotherapy and surgery depend upon the stage of the disease and have resulted in higher rates of relapse. Hence, there is a need for alternative treatments. Differential antigen expression levels have been utilised for early detection of the cancer and could be employed in vaccination strategies using nucleic acids. In this review the different vaccination strategies in Ovarian cancer are discussed and reviewed. Nucleic acid vaccination strategies have been proven to produce a higher CD8<jats:sup>+<\/jats:sup> CTL response alongside CD4<jats:sup>+<\/jats:sup> T-cell response when compared to other vaccination strategies and thus provide a good arena for antitumour immune therapy. DNA and mRNA need to be delivered into the intracellular matrix. To overcome ineffective naked delivery of the nucleic acid cargo, a suitable delivery system is required. This review also considers the suitability of cell penetrating peptides as a tool for nucleic acid vaccine delivery in ovarian cancer.<\/jats:p>","DOI":"10.3389\/fbioe.2022.953887","type":"journal-article","created":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T15:11:11Z","timestamp":1667833871000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Nucleic acid vaccination strategies for ovarian cancer"],"prefix":"10.3389","volume":"10","author":[{"given":"Chayanika","family":"Saha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Bojdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Dunne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Kumar","family":"Duary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen O.","family":"McCarthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e24270","DOI":"10.4161\/onci.24270","article-title":"The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target for immunotherapy of ovarian serous carcinoma","volume":"2","author":"Agarwal","year":"2013","journal-title":"Oncoimmunology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/cells9030719","article-title":"Ovarian cancer, cancer stem cells and current treatment strategies: A potential role of magmas in the current treatment methods","volume":"149","author":"Ahmed","year":"2020","journal-title":"Cells"},{"key":"B3","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","article-title":"Pathogen recognition and innate immunity","volume":"124","author":"Akira","year":"2006","journal-title":"Cell"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","article-title":"Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies","volume":"72","author":"Antoniou","year":"2003","journal-title":"Am. J. Hum. Genet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"17136","DOI":"10.1038\/s41598-018-35567-1","article-title":"Expression of the POTE gene family in human ovarian cancer","volume":"8","author":"Barger","year":"2018","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.vaccine.2013.12.049","article-title":"Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector","volume":"32","author":"Batchu","year":"2014","journal-title":"Vaccine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ygyno.2019.08.029","article-title":"Defining the molecular evolution of extrauterine high grade serous carcinoma","volume":"155","author":"Beirne","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/0008-5472.can-05-3014","article-title":"POTE paralogs are induced and differentially expressed in many cancers","volume":"66","author":"Bera","year":"2006","journal-title":"Cancer Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.7150\/jca.16450","article-title":"Evaluation of attenuated tumor antigens and the implications for peptide-based cancer vaccine development","volume":"8","author":"Berry","year":"2017","journal-title":"J. Cancer."},{"key":"B10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.21037\/tcr.2016.11.76","article-title":"Regulation of cytotoxic T-cell responses by p53 in cancer","volume":"5","author":"Braun","year":"2016","journal-title":"Transl. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1002\/cam4.2378","article-title":"Final analysis of a phase I\/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients","volume":"8","author":"Brown","year":"2019","journal-title":"Cancer Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1186\/s12885-018-4880-x","article-title":"Validity and prognostic significance of sperm protein 17 as a tumor biomarker for epithelial ovarian cancer: A retrospective study","volume":"18","author":"Brunette","year":"2018","journal-title":"BMC Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/pharmaceutics12020158","article-title":"Dendritic cell vaccines for cancer immunotherapy: The role of human conventional type 1 dendritic cells","volume":"12","author":"Calmeiro","year":"2020","journal-title":"Pharmaceutics"},{"key":"B14","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41416-018-0191-x","article-title":"Transcription factors wt1 and p53 combined: A prognostic biomarker in ovarian cancer","volume":"119","author":"Carter","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3233\/cbm-130360","article-title":"Overexpression of PIWI proteins in human stage III epithelial ovarian cancer with lymph node metastasis","volume":"13","author":"Chen","year":"2013","journal-title":"Cbm"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1002\/ijc.24296","article-title":"Cancer\/testis antigen CT45: Analysis of mRNA and protein expression in human cancer","volume":"124","author":"Chen","year":"2009","journal-title":"Int. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejpb.2018.02.029","article-title":"DNA vaccination for cervical cancer : Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system","volume":"127","author":"Cole","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B18","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejpb.2018.02.029","article-title":"DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system","volume":"127","author":"Cole","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.actbio.2019.07.003","article-title":"Acta Biomaterialia DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen","volume":"96","author":"Cole","year":"2019","journal-title":"Acta Biomater."},{"key":"B20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/21645515.2016.1248008","article-title":"Dissolving microneedles for DNA vaccination: Improving functionality via polymer characterization and RALA complexation","volume":"13","author":"Cole","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cell.2018.08.065","article-title":"Multi-level proteomics identifies CT45 as a chemosensitivity mediator and immunotherapy target in ovarian cancer","volume":"175","author":"Coscia","year":"2018","journal-title":"Cell"},{"key":"B22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/s0264-410x(96)00183-1","article-title":"Adjuvants--a classification and review of their modes of action","volume":"15","author":"Cox","year":"1997","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/path.4263","article-title":"Through the glass darkly: Intraepithelial neoplasia, top\u2010down differentiation, and the road to ovarian cancer","volume":"231","author":"Crum","year":"2013","journal-title":"J. Pathology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.trsl.2015.07.008","article-title":"Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives","volume":"168","author":"Constantino","year":"2016","journal-title":"Transl. Res.: J. lab. clin. med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e104099","DOI":"10.1371\/journal.pone.0104099","article-title":"Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer","volume":"9","author":"Daudi","year":"2014","journal-title":"PLoS One"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.biotechadv.2015.10.013","article-title":"Peptide vaccines in breast cancer: The immunological basis for clinical response","volume":"33","author":"de Paula Peres","year":"2015","journal-title":"Biotechnol. Adv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nrc1782","article-title":"Paradoxical roles of the immune system during cancer development","volume":"6","author":"de Visser","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.7314\/apjcp.2014.15.22.9739","article-title":"Hormone receptor, HER2\/NEU and EGFR expression in ovarian carcinoma - is here a prognostic phenotype?","volume":"15","author":"Demir","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.ccr-18-0573","article-title":"T-Cell responses to TP53 \"hotspot\" mutations and unique neoantigens expressed by human ovarian cancers","volume":"24","author":"Deniger","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"11670","DOI":"10.1002\/jcp.27826","article-title":"Intracellular delivery of nucleic acid by cell-permeable hPP10 peptide","volume":"234","author":"Ding","year":"2019","journal-title":"J. Cell Physiol."},{"key":"B30","first-page":"2778","article-title":"Overexpression of MAGE\/GAGE genes in paclitaxel\/doxorubicin-resistant human cancer cell lines","volume":"9","author":"Duan","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"22975","DOI":"10.1016\/s0378-1119(99)00042-6","article-title":"TRAG-3, a novel gene, isolated from a taxol-resistant ovarian carcinoma cell line","volume":"229","author":"Duan","year":"1999","journal-title":"Gene"},{"key":"B32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1385\/mb:21:2:129","article-title":"The development and use of vaccine adjuvants, applied biochemistry and Biotechnology - Part B molecular Biotechnology","volume":"21","author":"Edelman","year":"2002","journal-title":"Mol. Biotechnol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2217\/imt.15.29","article-title":"MAGE-A3: An immunogenic target used in clinical practice","volume":"7","author":"Esfandiary","year":"2015","journal-title":"Immunotherapy"},{"key":"B35","first-page":"298","article-title":"Cancer testis antigen OY-TES-1: Analysis of protein expression in ovarian cancer with tissue microarrays","volume":"36","author":"Fan","year":"2015","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress","volume":"1313","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/978-3-319-66095-0_13","article-title":"The current role of cell-penetrating peptides in cancer therapy","volume":"1030","author":"Feni","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ijpharm.2005.03.035","article-title":"Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model","volume":"298","author":"Foged","year":"2005","journal-title":"Int. J. Pharm."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","article-title":"PARP inhibitors in ovarian cancer","volume":"73","author":"Franzese","year":"2019","journal-title":"Cancer Treat. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: A new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10080276","article-title":"Sperm protein 17 expression by murine epithelial ovarian cancer cells and its impact on tumor progression","volume":"10","author":"Gao","year":"2018","journal-title":"Cancers (Basel)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1158\/1078-0432.ccr-06-2340","article-title":"Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer","volume":"13","author":"Garg","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/bjc.1998.585","article-title":"MAGE, BAGE and GAGE: Tumour antigen expression in benign and malignant ovarian tissue","volume":"78","author":"Gillespie","year":"1998","journal-title":"Br. J. Cancer"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s00262-006-0269-9","article-title":"Assessment of CD4+ T cells specific for the tumor antigen SSX-1 in cancer-free individuals","volume":"56","author":"Godefroy","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"B45","doi-asserted-by":"publisher","first-page":"27330807","DOI":"10.1186\/s40425-016-0137-x","article-title":"Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial","volume":"4","author":"Gray","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/1078-0432.ccr-05-2578","article-title":"Detection and functional analysis of CD8+ T cells specific for PRAME: A target for T-cell therapy","volume":"12","author":"Griffioen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B47","first-page":"1252","article-title":"Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer","volume":"7","author":"Gupta","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.3390\/molecules24050927","article-title":"Recent advances in cell penetrating peptide-based anticancer therapies","volume":"24","author":"Habault","year":"2019","journal-title":"Molecules"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/jco.2015.62.3397","article-title":"Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"Jco"},{"key":"B50","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ijc.11565","article-title":"A-kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis","volume":"108","author":"Hasegawa","year":"2004","journal-title":"Int. J. Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1001\/jamaoncol.2015.2736","article-title":"Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: A randomized clinical trial","volume":"1","author":"Heery","year":"2015","journal-title":"JAMA Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/ni1004-971","article-title":"The interface between innate and adaptive immunity","volume":"5","author":"Hoebe","year":"2004","journal-title":"Nat. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"5733","DOI":"10.4049\/jimmunol.166.9.5733","article-title":"Improving vaccine potency through intercellular spreading and enhanced MHC class I presentation of antigen","volume":"166","author":"Hung","year":"2022","journal-title":"J. Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ygyno.2005.09.052","article-title":"Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer","volume":"101","author":"Hylander","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1158\/1078-0432.ccr-17-2499","article-title":"Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients","volume":"24","author":"Kalli","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/1479-5876-11-149","article-title":"A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer","volume":"11","author":"Kandalaft","year":"2013","journal-title":"J. Transl. Med."},{"key":"B57","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: Update on toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat. Immunol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"46120","DOI":"10.18632\/oncotarget.10028","article-title":"Expression of tumor antigens on primary ovarian cancer cells compared to established ovarian cancer cell lines","volume":"7","author":"Kloudov\u00e1","year":"2016","journal-title":"Oncotarget"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/bjc.2014.567","article-title":"Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: Implications for clinical testing. An ovarian tumour tissue analysis consortium study","volume":"111","author":"K\u00f6bel","year":"2014","journal-title":"Br. J. Cancer"},{"key":"B60","doi-asserted-by":"publisher","first-page":"7621","DOI":"10.1158\/1078-0432.ccr-17-1159","article-title":"A complex network of tumor microenvironment in human high-grade serous ovarian cancer","volume":"23","author":"Kreuzinger","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"53124","DOI":"10.18632\/oncotarget.18163","article-title":"Role of A-Kinase anchor protein (AKAP4) in growth and survival of ovarian cancer cells","volume":"8","author":"Kumar","year":"2017","journal-title":"Oncotarget"},{"key":"B62","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum. Pathol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1097\/pas.0b013e3181cf3d79","article-title":"The origin and pathogenesis of epithelial ovarian cancer: A proposed unifying theory","volume":"34","author":"Kurman","year":"2010","journal-title":"Am. J. Surg. Pathol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/j.1365-2567.2011.03457.x","article-title":"Complexity of dendritic cell subsets and their function in the host immune system","volume":"133","author":"Kushwah","year":"2011","journal-title":"Immunology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.trecan.2019.06.004","article-title":"Combined PARP and immune checkpoint inhibition in ovarian cancer","volume":"5","author":"Lee","year":"2019","journal-title":"Trends Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/978-1-59745-483-4","article-title":"Micro and nano technologies in Bioanalysis. Preface","volume":"544","author":"Lee","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.clinbiochem.2013.03.010","article-title":"Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients","volume":"46","author":"Leung","year":"2013","journal-title":"Clin. Biochem."},{"key":"B68","first-page":"6","article-title":"BORIS\/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer","volume":"13","author":"Link","year":"2013","journal-title":"Cancer Immun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3727\/000000006783980892","article-title":"Expression of MDR1 in epithelial ovarian cancer and its association with disease progression","volume":"16","author":"Lu","year":"2007","journal-title":"Oncol. Res."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20190656","article-title":"Expression of RRBP1 in epithelial ovarian cancer and its clinical significance","volume":"39","author":"Ma","year":"2019","journal-title":"Biosci. Rep."},{"key":"B71","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00428-006-0346-7","article-title":"Taxol-resistance-associated gene-3 (TRAG-3\/CSAG2) expression is predictive for clinical outcome in ovarian carcinoma patients","volume":"450","author":"Materna","year":"2007","journal-title":"Virchows Arch."},{"key":"B72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jconrel.2014.06.048","article-title":"Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery","volume":"189","author":"Mccarthy","year":"2014","journal-title":"J. Control Release"},{"key":"B73","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1097\/PGP.0000000000000336","article-title":"The fallopian tube origin and primary site assignment in extrauterine high-grade serous carcinoma: Findings of a survey of pathologists and clinicians","volume":"36","author":"McCluggage","year":"2017","journal-title":"Int. J. Gynecol. Pathol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s00262-012-1384-4","article-title":"Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors","volume":"62","author":"McCormack","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"B75","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12645-018-0040-x","article-title":"Gene therapy with RALA\/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer","volume":"9","author":"Mccrudden","year":"2018","journal-title":"Cancer Nanotechnol."},{"key":"B76","doi-asserted-by":"crossref","DOI":"10.5772\/61297","article-title":"Multifunctional delivery systems for cancer gene therapy","volume-title":"Gene therapy: Principles and challenges","author":"Mcerlean","year":"2015"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1093\/annonc\/mdu211","article-title":"Final report of the phase I\/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients","volume":"25","author":"Mittendorf","year":"2014","journal-title":"Ann. Oncol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1007\/s00262-008-0540-3","article-title":"The E75 HER2\/neu peptide vaccine","volume":"57","author":"Mittendorf","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"B79","doi-asserted-by":"publisher","first-page":"7164","DOI":"10.1158\/1078-0432.ccr-11-0649","article-title":"A pilot study of MUC-1\/CEA\/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer","volume":"17","author":"Mohebtash","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1586\/erv.11.149","article-title":"Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications","volume":"11","author":"Muhammad","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"B81","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s00005-011-0129-y","article-title":"Cancer vaccines . Any future","volume":"59","author":"Myc","year":"2011","journal-title":"Arch. Immunol. Ther. Exp. Warsz."},{"key":"B82","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.nano.2018.09.004","article-title":"Protein-based nanoparticles in cancer vaccine development","volume":"15","author":"Neek","year":"2019","journal-title":"Nanomedicine Nanotechnol. Biol. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1177\/1758834017714993","article-title":"BRCA mutation in ovarian cancer: Testing, implications and treatment considerations","volume":"9","author":"Neff","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4895","DOI":"10.2147\/ijn.s171361","article-title":"Macropinocytosis activated by oncogenic Dbl enables specific targeted delivery of Tat\/pDNA nano-complexes into ovarian cancer cells","volume":"13","author":"Niu","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"288","author":"Odunsi","year":"2017","journal-title":"Ann. Oncol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann. Oncol."},{"key":"B87","first-page":"6076","article-title":"NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer","volume":"63","author":"Odunsi","year":"2003","journal-title":"Cancer Res."},{"key":"B88","doi-asserted-by":"publisher","first-page":"65917","DOI":"10.18632\/oncotarget.19579","article-title":"In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)","volume":"8","author":"Pankov","year":"2017","journal-title":"Oncotarget"},{"key":"B89","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ymthe.2018.11.014","article-title":"Engineered DNA vaccination against follicle-stimulating hormone receptor delays ovarian cancer progression in animal models","volume":"27","author":"Perales-Puchalt","year":"2019","journal-title":"Mol. Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.vaccine.2005.01.107","article-title":"Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity","volume":"24","author":"Petrovsky","year":"2006","journal-title":"Vaccine"},{"key":"B91","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J. Pathol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hep.510310237","article-title":"Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major Hepatitis B surface antigen","volume":"31","author":"Rahman","year":"2000","journal-title":"Hepatology"},{"key":"B93","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/sj.gt.3301117","article-title":"The promise of nucleic acid vaccines","volume":"7","author":"Restifo","year":"2000","journal-title":"Gene Ther."},{"key":"B94","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1158\/1078-0432.ccr-12-2189","article-title":"Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients","volume":"18","author":"Sabbatini","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"B95","doi-asserted-by":"publisher","first-page":"15818","DOI":"10.18632\/oncotarget.24530","article-title":"WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis","volume":"9","author":"Sallum","year":"2018","journal-title":"Oncotarget"},{"key":"B96","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.canlet.2012.07.001","article-title":"Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma","volume":"330","author":"Shahzad","year":"2013","journal-title":"Cancer Lett."},{"key":"B97","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1080\/15592294.2019.1581590","article-title":"Epigenetic activation of POTE genes in ovarian cancer","volume":"14","author":"Sharma","year":"2019","journal-title":"Epigenetics"},{"key":"B98","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ygyno.2005.06.006","article-title":"A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer","volume":"99","author":"Sharma","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ygyno.2005.06.006","article-title":"A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer","volume":"99","author":"Sharma","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1159\/000494467","article-title":"Overexpression of KIF2A is suppressed by miR-206 and associated with poor prognosis in ovarian cancer","volume":"50","author":"Sheng","year":"2018","journal-title":"Cell Physiol. Biochem."},{"key":"B101","doi-asserted-by":"publisher","first-page":"a026252","DOI":"10.1101\/cshperspect.a026252","article-title":"TP53Mutations in breast and ovarian cancer","volume":"7","author":"Silwal-Pandit","year":"2017","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"150591","DOI":"10.1155\/2010\/150591","article-title":"The SSX family of cancer-testis antigens as target proteins for tumor therapy","volume":"2010","author":"Smith","year":"2010","journal-title":"Clin. Dev. Immunol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.3390\/ijms20112776","article-title":"A critical review of electroporation as A plasmid delivery system in mouse skeletal muscle","volume":"20","author":"Soko\u0142owska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B104","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/1521-4141(200203)32:3<731:AID-IMMU731>3.0.CO;2-H","article-title":"In vivo activation of melanoma-specific CD8 + T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells","volume":"32","author":"Speiser","year":"2002","journal-title":"Eur. J. Immunol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/pgp.0000000000000470","article-title":"MAGE-A4 and MAGE-A1 immunohistochemical expression in high-grade endometrial cancer","volume":"38","author":"Srdeli\u0107","year":"2019","journal-title":"Int. J. Gynecol. Pathol."},{"key":"B106","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/00313020802320697","article-title":"WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis","volume":"40","author":"Stewart","year":"2008","journal-title":"Pathology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ijc.11617","article-title":"Expression of sperm protein 17 (Sp17) in ovarian cancer","volume":"108","author":"Straughn","year":"2004","journal-title":"Int. J. Cancer"},{"key":"B108","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/s0090-8258(03)00472-4","article-title":"First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer","volume":"90","author":"Stuart","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"B109","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B111","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jconrel.2016.05.058","article-title":"Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery","volume":"235","author":"Tawde","year":"2016","journal-title":"J. Control. Release"},{"key":"B112","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/intimm\/dxw015","article-title":"Vaccine adjuvants as potential cancer immunotherapeutics","volume":"28","author":"Temizoz","year":"2016","journal-title":"Intimm"},{"key":"B113","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3390\/cells8020128","article-title":"Regulation of survivin isoform expression by GLI proteins in ovarian cancer","volume":"8","author":"Trnski","year":"2019","journal-title":"Cells"},{"key":"B114","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/s41416-018-0217-4","article-title":"BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer","volume":"119","author":"Tsibulak","year":"2018","journal-title":"Br. J. Cancer"},{"key":"B115","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/(SICI)1097-0215(19980703)77:1<19::AID-IJC4>3.0.CO;2-2","article-title":"Expression of SSX genes in human tumors","volume":"77","author":"T\u00fcreci","year":"1998","journal-title":"Int. J. Cancer [Internet]"},{"key":"B116","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2217\/imt.10.56","article-title":"Enhancement of dendritic cells as vaccines for cancer","volume":"2","author":"Turnis","year":"2010","journal-title":"Immunotherapy"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/adhm.201601412","article-title":"Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide","volume":"6","author":"Udhayakumar","year":"2017","journal-title":"Adv. Healthc. Mat."},{"key":"B118","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"key":"B119","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1158\/1078-0432.ccr-05-1902","article-title":"Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells","volume":"12","author":"Valmori","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"B120","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/bjc.2013.45","article-title":"Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer","volume":"108","author":"van der Gun","year":"2013","journal-title":"Br. J. Cancer"},{"key":"B121","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ijpharm.2013.06.010","volume":"453","author":"Van der Heijden","year":"2013","journal-title":"Int. J. Pharm. Long term Stab. lyophilized plasmid DNA pDERMATT"},{"key":"B122","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/j.1365-2559.2010.03667.x","article-title":"Expression of aberrantly glycosylated Mucin-1 in ovarian cancer","volume":"57","author":"Van Elssen","year":"2010","journal-title":"Histopathology"},{"key":"B123","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000086958","article-title":"HER2\/neu oncoprotein overexpression in epithelial ovarian cancer : Evaluation of its prevalence and prognostic significance. Clinical study","volume":"68","author":"Verri","year":"2005","journal-title":"Oncology"},{"key":"B124","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000086958","article-title":"HER2\/neu oncoprotein overexpression in epithelial ovarian cancer: Evaluation of its prevalence and prognostic significance. Clinical study","volume":"68","author":"Verri","year":"2020","journal-title":"Oncology"},{"key":"B125","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s13046-018-0906-0","article-title":"miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGF\u03b2 pathway","volume":"37","author":"Wang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B126","doi-asserted-by":"publisher","first-page":"e2803","DOI":"10.1097\/MD.0000000000002803","article-title":"Prognostic value of KIF2A and HER2-neu overexpression in patients with epithelial ovarian cancer","volume":"95","author":"Wang","year":"2016","journal-title":"Med. Baltim."},{"key":"B127","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s13277-014-2859-z","article-title":"Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer","volume":"36","author":"Wang","year":"2015","journal-title":"Tumor Biol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cr.2016.155","article-title":"Immune targets and neoantigens for cancer immunotherapy and precision medicine","volume":"27","author":"Wang","year":"2016","journal-title":"Cell Res."},{"key":"B129","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijpharm.2011.07.013","article-title":"Review Design of multifunctional non-viral gene vectors to overcome physiological barriers: Dilemmas and strategies","volume":"427","author":"Wang","year":"2012","journal-title":"Int. J. Pharm."},{"key":"B130","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.3892\/ijmm.2018.3870","article-title":"Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses","volume":"42","author":"Wang","year":"2018","journal-title":"Int. J. Mol. Med."},{"key":"B131","first-page":"21","article-title":"DNA methylation-dependent regulation of BORIS\/CTCFL expression in ovarian cancer","volume":"7","author":"Woloszynska-Read","year":"2007","journal-title":"Cancer Immun."},{"key":"B132","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1158\/1078-0432.ccr-10-2315","article-title":"Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: Association with the BORIS\/CTCF expression ratio and advanced stage","volume":"17","author":"Woloszynska-Read","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"B133","doi-asserted-by":"publisher","first-page":"10499","DOI":"10.1007\/s13277-016-4944-y","article-title":"MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1","volume":"37","author":"Wu","year":"2016","journal-title":"Tumor Biol."},{"key":"B134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-018-0475-z","article-title":"Cancer-testis antigens in ovarian cancer: Implication for biomarkers and therapeutic targets","volume":"12","author":"Xie","year":"2019","journal-title":"J. Ovarian Res."},{"key":"B135","first-page":"6453","article-title":"Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms","volume":"9","author":"Yakirevich","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"B136","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cancergencyto.2003.08.021","article-title":"Epigenetic regulation of the taxol resistance-associated gene TRAG-3 in human tumors","volume":"151","author":"Yao","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"B137","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1471-2407-10-163","article-title":"Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines","volume":"10","author":"Zhang","year":"2010","journal-title":"BMC Cancer"},{"key":"B138","doi-asserted-by":"publisher","first-page":"45352","DOI":"10.18632\/oncotarget.9977","article-title":"PRAME expression and promoter hypomethylation in epithelial ovarian cancer","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B139","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1080\/15592294.2015.1062206","article-title":"DNA hypomethylation-mediated activation ofCancer\/Testis Antigen 45(CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer","volume":"10","author":"Zhang","year":"2015","journal-title":"Epigenetics"},{"key":"B140","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/21655979.2021.1916271","article-title":"Cisatracurium inhibits the growth and induces apoptosis of ovarian cancer cells by promoting lincRNA-p21","volume":"12","author":"Zhu","year":"2021","journal-title":"Bioengineered"}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.953887\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T15:11:23Z","timestamp":1667833883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2022.953887\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,7]]},"references-count":140,"alternative-id":["10.3389\/fbioe.2022.953887"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2022.953887","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,7]]},"article-number":"953887"}}